Equities

Zomedica Corp

Zomedica Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.1295
  • Today's Change-0.002 / -1.30%
  • Shares traded3.98m
  • 1 Year change-23.37%
  • Beta1.0563
Data delayed at least 15 minutes, as of Nov 22 2024 21:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zomedica Corp. is a veterinary health company. The Company is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The Company's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.

  • Revenue in USD (TTM)26.73m
  • Net income in USD-62.19m
  • Incorporated2013
  • Employees144.00
  • Location
    Zomedica Corp100 Phoenix Drive, Suite 125ANN ARBOR 48108United StatesUSA
  • Phone+1 (734) 369-2555
  • Fax+1 (780) 440-1377
  • Websitehttps://zomedica.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CRYO-CELL International, Inc.31.84m-8.93m66.92m82.00------2.10-1.08-1.083.86-1.190.47989.354.78388,274.30-13.450.4686-18.450.709973.6670.09-28.040.81330.5699------3.321.41-443.57--60.30--
Exagen Inc55.75m-16.93m68.15m174.00--5.34--1.22-0.9383-0.93833.090.73451.07--4.22320,408.00-32.39-30.21-39.53-33.7558.8054.86-30.36-55.36---6.880.6148--15.3310.1350.01--33.00--
23andMe Holding Co.193.26m-615.31m77.83m560.00--0.8187--0.4027-25.27-25.277.843.950.34516.93198.52345,107.20-109.86---142.15--46.5146.35-318.39-121.631.14--0.00---26.66-13.01-113.92---19.09--
Cardiff Lexington Corp7.22m-2.84m97.74m10.000.7895----13.548.233.610.96050.58380.3436--0.542722,096.00-9.27---25.14--49.3262.01-26.98-----0.00990.4916----39.71--------
American Well Corp254.04m-214.08m122.71m1.10k--0.3637--0.483-14.54-14.5417.2222.020.454526.313.74230,104.20-38.46-28.25-49.63-32.6634.8040.51-84.63-121.272.88--0.00---6.5517.85-149.66--51.49--
Zomedica Corp26.73m-62.19m128.57m144.00--0.6338--4.81-0.0635-0.06350.02730.2070.10931.7714.31185,604.20-25.43-14.03-26.22-14.4569.64---232.70-220.9810.15--0.00--33.05---102.93--89.85--
Longduoduo Co Ltd7.39m1.26m150.33m49.00119.74213.98102.5920.340.04180.04180.24630.02344.17422.8061.99150,812.9076.89--1,467.79--97.65--18.45--1.31--0.00--93.52--3,311.69------
Nutex Health Inc292.00m-41.13m173.39m800.00--2.75--0.5938-8.93-8.9360.2011.590.636190.724.82365,000.50-7.06-69.35-8.65-84.8523.2410.97-11.10-102.851.741.440.7824--12.93428.2289.22------
Joint Corp120.80m-16.86m173.51m444.00--8.46--1.44-1.14-1.148.101.371.36--30.39272,062.20-18.924.32-30.066.0590.7090.28-13.953.68--1,593.990.0022--16.2426.27-1,656.09--35.09--
Biodesix Inc65.56m-43.82m174.56m217.00--6.27--2.66-0.3941-0.39410.56630.19150.6918--9.49302,129.00-46.24-55.60-60.89-80.9477.7259.53-66.84-105.15---3.910.5647--28.4619.1620.32--106.31--
American Oncology Network Inc1.59bn-14.57m179.17m1.53k------0.1125-1.72-1.7294.45-2.424.0434.6411.681,044,447.00-13.15------5.27---3.26--1.11-9.600.6406--11.27----------
Data as of Nov 22 2024. Currency figures normalised to Zomedica Corp's reporting currency: US Dollar USD

Institutional shareholders

7.85%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 202447.96m4.89%
Geode Capital Management LLCas of 30 Sep 20249.93m1.01%
BlackRock Fund Advisorsas of 30 Sep 20249.82m1.00%
SSgA Funds Management, Inc.as of 30 Sep 20243.51m0.36%
Brown Brothers Harriman & Co. (Investment Management)as of 30 Sep 20242.47m0.25%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 20241.80m0.18%
Charles Schwab Investment Management, Inc.as of 30 Sep 2024412.33k0.04%
Vanguard Global Advisers LLCas of 30 Sep 2024370.51k0.04%
Orion Portfolio Solutions LLCas of 30 Sep 2024357.15k0.04%
LPL Financial LLCas of 30 Sep 2024285.98k0.03%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.